BioSpace News Archive

With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.

Bactiguard has received a new order from Well Lead Medical in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has signed a Master Services Agreement with Worldwide Clinical Trials

Shineco, Inc. (“Shineco” or the “Company"; Nasdaq: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, hemp products, and various health and well-being focused plant-based products in China, announced today that the Company received a letter from Nasdaq Listing Qualifications Staff (“Nasdaq”) that the Company has been granted an additional 180-day grace period or until June 20, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that JAMA Network Open (www.jamanetwork.com) published results of SUNRISE 1 (Study 304), a pivotal Phase 3 head-to-head study that compared DAYVIGO™ (lemborexant) to placebo and an active comparator in patients with insomnia disorde

CEL-SCI Corporation (NYSE American: CVM) announced the closing of an underwritten public offering of 606,395 shares of its common stock at a price of $9.07 per share, for total gross proceeds of approximately $5.5 million, before deducting underwriting discounts and other offering expenses payable by the Company.

Integrated care teams and care management tools led to 3,600 fewer bed days in a year

BeiGene, Ltd. announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration as a treatment for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies.

Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company’s varicella vaccine to prevent the varicella-zoster virus in children from 1 to 12 years old.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox, will resign from the Board effective March 31, 2020.